A5085208978- Acute Myeloid Leukemia Research
- Acute Lymphoblastic Leukemia research
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Histone Deacetylase Inhibitors Research
- Cancer therapeutics and mechanisms
- Economic and Financial Impacts of Cancer
- Neutrophil, Myeloperoxidase and Oxidative Mechanisms
- Immune cells in cancer
- Synthetic Organic Chemistry Methods
- Hematopoietic Stem Cell Transplantation
- Chronic Lymphocytic Leukemia Research
- Chronic Myeloid Leukemia Treatments
- Health Systems, Economic Evaluations, Quality of Life
- Multiple Myeloma Research and Treatments
- Protein Degradation and Inhibitors
- Extracellular vesicles in disease
- Hematological disorders and diagnostics
- SARS-CoV-2 and COVID-19 Research
- Blood disorders and treatments
- Parvovirus B19 Infection Studies
- Inflammatory Biomarkers in Disease Prognosis
- Coagulation, Bradykinin, Polyphosphates, and Angioedema
- Nuclear Structure and Function
- COVID-19 and healthcare impacts
- Autoimmune and Inflammatory Disorders Research
Vanderbilt University Medical Center
2023-2024
Vanderbilt University
2024
Albert Einstein College of Medicine
2019-2024
Montefiore Medical Center
2019-2024
The Bronx Defenders
2024
Leningrad Regional Cancer Center
2018
Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is new standard of care for elderly patients with acute myeloid leukemia (AML) and being evaluated in myelodysplastic syndrome (MDS). Current dosing HMA/VEN relies on suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose (LDDec) has demonstrated activity malignancies. To overcome severe myelosuppression often seen HMA/VEN, we a VEN LDDec and/or frail...
Neutrophil Extracellular Traps (NETs) are large neutrophil-derived structures composed of decondensed chromatin, cytosolic, and granule proteins. NETs play an important role in fighting infection, inflammation, thrombosis, tumor progression processes, yet their fast reliable identification has been challenging. Smudge cells (SCs) a subcategory white identified by CellaVision®, hematology autoanalyzer routinely used clinical practice that uses digital imaging to generate "manual"...
Secondary prostate cancer typically occurs from direct seeding of a renal or bladder tumor. Metastasis via hematogenous spread is exceedingly rare and identified incidentally at autopsy. This report describes 72-year-old male with lung adenocarcinoma initially staged as Stage IA2 who developed oligometastatic disease the prostate. He was treated radiation therapy found to have hypermetabolic focus in gland during surveillance PET/CT imaging 6 months following treatment. Subsequent biopsy...
<sec> <title>BACKGROUND</title> Cancer continues to be a significant public health concern. According the American Society, in 2022, there were nearly 2 million new cancer cases and over 600,000 cancer-related deaths U.S. (1) . Receiving diagnosis brings untold physical, emotional, psychological distress patient their caregivers. While survival rates of patients have improved years due increasing treatment options advances therapy, cost care has become challenge oncology. Financial toxicity...
Abstract Background Digitized microscopy such as CellaVision® technology has revolutionized the laboratory. Smudge cells, also called basket are usually seen in lymphoproliferative disorders representing remnants from degenerated lymphocytes (DLs). classifies DLs and web-like smudge cells. The morphology of is compatible with Neutrophil Extracellular Traps (NETs) where extracellular decondensed DNA chromatin network formed one several neutrophilic reactions to stress. Currently, we lack...
Autologous stem cell transplantation in an older adult populationOver the past decade there has been a remarkable progress treatment of multiple myeloma (MM) and non-Hodgkin lymphoma (NHL).Nevertheless, autologous transplant (ASCT) remains integral part care for patients with MM, one few curative options relapsed/refractory (R/R) NHL.Historically, arbitrary age 65 used to determine patient's eligibility ASCT.This stems from fact that majority prospective studies evaluating efficacy ASCT MM...
e18907 Background: Financial toxicity is an increasingly recognized challenge in cancer care delivery due to the costs of treatment. Increased burden financial associated with poor quality life and a healthcare barrier for patients from underserved communities. Here we report on degrees socioeconomically disadvantageous predominantly minority backgrounds undergoing treatment hematologic malignancy. Methods: This prospective ongoing survey-based study Montefiore Cancer Center, Bronx, NY, that...
<div>AbstractPurpose:<p>Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is new standard of care for elderly patients with acute myeloid leukemia (AML) and being evaluated in myelodysplastic syndrome (MDS). Current dosing HMA/VEN relies on suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose (LDDec) has demonstrated activity malignancies. To overcome severe myelosuppression often seen...
<p>Supplementary table on representativeness</p>
<p>Supplementary table on representativeness</p>
<div>AbstractPurpose:<p>Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is new standard of care for elderly patients with acute myeloid leukemia (AML) and being evaluated in myelodysplastic syndrome (MDS). Current dosing HMA/VEN relies on suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose (LDDec) has demonstrated activity malignancies. To overcome severe myelosuppression often seen...
<p>Supplementary table on representativeness</p>
<div>AbstractPurpose:<p>Venetoclax (VEN) added to the hypomethylating agents (HMA) decitabine or azacitidine is new standard of care for elderly patients with acute myeloid leukemia (AML) and being evaluated in myelodysplastic syndrome (MDS). Current dosing HMA/VEN relies on suppression through cytotoxicity which also impacts normal hematopoiesis. A regimen using once-weekly low-dose (LDDec) has demonstrated activity malignancies. To overcome severe myelosuppression often seen...
<p>Supplementary table on representativeness</p>
Background: Hypomethylating agents (HMAs) (5-azacytidine or decitabine) combined with venetoclax (Ven) have become the new standard of care for patients acute myeloid leukemia (AML) who are unfit intensive chemotherapy. However, myelosuppression and infectious complications common adverse events currently approved HMA/Ven regimens, requiring dose interruptions/delays that often undermine treatment goals. Previous studies identified minimum decitabine needed to deplete DNA methyltransferase-1...